Premium
Alprazolam compared to amitriptyline in the treatment of major depression
Author(s) -
Eriksson B.,
Nagy A.,
Starmark J.E.,
Thelander U.
Publication year - 1987
Publication title -
acta psychiatrica scandinavica
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.849
H-Index - 146
eISSN - 1600-0447
pISSN - 0001-690X
DOI - 10.1111/j.1600-0447.1987.tb02851.x
Subject(s) - alprazolam , amitriptyline , depression (economics) , dose , anxiety , rating scale , medicine , anesthesia , antidepressant , psychology , psychiatry , developmental psychology , economics , macroeconomics
— In a double‐blind randomized study the therapeutic effect and safety of alprazolam was compared with amitriptyline in 81 outpatients suffering from major depression. Variable dosages of both drugs were used, the mean final dose of alprazolam being 3.05 and that of amitriptyline 130 mg. Both treatment groups improved steadily, assessed weekly with the use of the Hamilton Rating Scale for Depression, and no significant differences were found between the groups, either on comparison between single items or total scores. On several of the criteria used for assessment of treatment response, however, more patients responded to amitriptyline than to alprazolam. In an analysis of specific subgroups, patients whose depression was accompanied by retardation, those in whom there were no precipitating factors and those with low levels of anxiety, responded better to amitriptyline. Considerably fewer side effects were reported by patients receiving alprazolam. In particular, there was a significantly lower incidence of dry mouth, light‐headedness, tremor and tachycardia in patients receiving alprazolam compared with amitriptyline.